So -- do your own diligence, but it is hard to see how a retiree seeking a fat dividend, and holding for a ten year plus horizon. . . could ever get hurt, by owning this name. [An increasingly aging US population (with health insurance) clearly works in its favor.] In any event, here's the latest -- of the local color, from CEO Davis, yesterday:
. . .Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its post-Keytruda future with what it foresees as a host of major sales opportunities over the next decade.
Thanks in part to its recent acquisitions of Verona Pharma and Cidara Therapeutics, the company sees new growth drivers delivering potential annual revenue of more than $70 billion by the "mid-2030s," Merck said in its fourth-quarter and full-year earnings presentation (PDF).
To put the $70 billion number into context, Davis pointed to the figure as being more than double the $35 billion Keytruda is expected to pick up during its peak sales year in 2028. The oncology superstar is slated for a loss of exclusivity (LOE) in 2028, and a growing pipeline of Keytruda biosimilars is already lining up to take a shot at the drug’s massive market. . . .
Now you know -- but that's it, for the power alley, I'm afraid, for today. Grin.
नमस्ते
2 comments:
Sent email to old address. Make sure you check this out.
https://fdawhistleblower.substack.com/?r=21cyw4&utm_campaign=pub-share-checklist
Thanks, man!
I'll check it all out... but just fyi -- no separate email ever came through! Glad you have your own mega-phone on Substack now, though -- to be sure!
Namaste!
Post a Comment